08.30 · Coffee and Registration
09.00 · Chairman's Opening Remarks
Stephane Dhalluin
Director, Investigative Non-Clinical Safety
Department of Non-Clinical Development
UCB Pharma SA
09.15 · Predictive Toxicology: The Path Towards New and Safer Medicines
Stephane Dhalluin
Director, Investigative Non-Clinical Safety
Department of Non-Clinical Development
UCB Pharma SA
10.00 · Advances in Predictive Toxicology Applications Satisfying
Regulatory, Transparency, and Interoperablity Requirements
Barry Hardy
OpenTox Project Coordinator
Director, Douglas Connect
10.45 · Networking Coffee Break
11.15 · Epigenomics - Impact for Drug Safety Sciences
Jonathan Moggs
Head of Molecular Toxicology, Investigative Toxicology
Preclinical Safety, Translational Sciences
Novartis Institutes for BioMedical Research
12.00 · Novel In Vitro System for the Toxicological Evaluation of
Genotoxic Compounds
Phil Hewitt
Head of Molecular Toxicology
Merck Serono Research
12.45 · Networking Lunch
14.15 · Genotoxicity, Carcinogenicity and Non-Genotoxic Carcinogencity Screening Devices as Deselection Tools
Willem Schoonen
Senior Research Scientist
Department of Toxicology & Drug Disposition
Shering-Plough
15.00 · Strategies to Reduce Late-Stage Drug Attrition due to Mitochondrial Toxicity
James Dykens
Drug Safety R&D
Pfizer Inc.
15.45 · Networking Coffee Break
16.15 · Challenges and Promising Approaches for the Early Assessment of Human Adverse Drug Effects
Albert Li
President and CEO
In Vitro ADMET Laboratories LLC and
Advanced Pharmaceutical Sciences Inc.
17.00 · Predicting Neurotoxicity by Early Assessment of the Free Concentration of Drug in Brain
Hinnerk Boriss
CEO
Sovicell GmbH
17.45 · Open Discussion and Chair's Closing Comments
18.00 · End of Day One
08.30 · Coffee and Registration
09.00 · Chairman's Opening Remarks
Katya Tsaioun
CEO
Apredica
09.15 · ADME/Biopharmaceutics Profiling: Advances in Methods and Applications
Dongzhou (Jeffery) Liu
Medical Affairs and Clinical Development
New Product R&D
GlaxoSmithKline
10.00 · Translation of Cytotoxicity Biomarkers Detected with High Content Analysis from an In Vitro Predictive Model to an In Vivo Cell Model
Peter O'Brien(formerly of Pfizer)
Veterinary Clinical Pathologist
University College Dublin
10.45 · Networking Coffee Break
11.15 · A High-Throughput Quantitative Phenotypic Assay for Nematodes
Denis Dupuy
Group Leader - Genome Regulation and Evolution
Institut Europeen de Chimie et Biologie (Bordeaux)
12.00 · The Application of Physiologically Based PK Modeling in Drug Development
Vikash Sinha M.D.
Clinical Pharmacology Leader
Global Clinical Pharmacology and Pharmacokinetics
J & J Pharmaceutical Research & Development, Belgium
12.45 · Networking Lunch
14.15 · Building Virtual Human Populations for Assessing ADME
Amin Rostami-Hodjegan
Professor of Systems Pharmacology
The University of Manchester
Director of Scientific Research and Development
Simcyp Limited
15.00 · QSAR Fragment Approach: Theoretical Development of HCV
Protease Inhibitors
Tarmo Tamm
Head Research and Development
Molcode
15.45 · Networking Coffee Break
16.15 · What’s New in ADMET: Non-CYP Metabolism and Sub-Lethal Toxicity as a Predictor of Chronic Human Toxicity
Katya Tsaioun
CEO
Apredica
17.00 · Biliary Efflux Transporters in Liver Toxicity
Marton Jani
Head of Cellular Product Development
Solvo Biotechnology
17.30 · Use of Primary Cultures of Human Hepatocytes to Study Uptake Drug
Transporters
Roberto Tolando
Scientific Adviser, Europe
Celsis IVT
18.00 · Chair's Closing Comments and Close of Conference
Speakers, time of presentations, additions to/or subtractions from the program may occur at the sole discretion of the conference producers and promoters.